COMP <GO>
COLL vs ARDX // PIOTROSKI F-SCORE QUALITY
Collegium Pharmaceutical Inc. (NASDAQ) VS. Ardelyx Inc. (NASDAQ) • 15-METRIC TALLY: COLL 8
— ARDX 1
▲ PIOTROSKI F-SCORE QUALITY LEADER: COLL
LAST: $24.03 (+3.44%) • MKT CAP: $782.3M
piotroski-score
7/9
LAST: $3.10 (0.00%) • MKT CAP: $772.5M
piotroski-score
4/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. ARDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COLL | ARDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 90.30% | -31.00 | ARDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -32.70% | +117.70 | COLL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -5.69% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 23.00% | -10.10% | +33.10 | COLL | /operating-margins <GO> |
| Net Profit Margin | 8.10% | -15.20% | +23.30 | COLL | /net-margins <GO> |
| Revenue Growth (YoY) | 23.60% | 22.10% | +1.50 | COLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.27 | 0.20 | +1.07 | COLL | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 4/9 | +3.00 | COLL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 42.1 | +16.90 | COLL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $782.3M | $772.5M | $9.8M | COLL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COLL REV | ARDX REV | COLL GROSS % | ARDX GROSS % | COLL FCF | ARDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $407.3M | 59.3% | 90.3% | $327.6M | -$44.0M |
| FY 2024 | $631.4M | $333.6M | 59.8% | 84.8% | $203.3M | -$45.8M |
| FY 2023 | $566.8M | $124.5M | — | — | $274.7M | -$89.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
ARDX // BETA —